title: Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.
abstract: OBJECTIVE
  To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments.
  
  
  METHODS
  Recruitment criteria were age 18-65 years, no history of thrombosis, positivity for lupus anticoagulant and/or IgG/IgM anticardiolipin antibody (aCL) on > or =2 occasions at least 6 weeks apart. Demographic, laboratory and clinical parameters were collected at enrolment and at the time of the thrombotic event.
  
  
  RESULTS
  370 patients/subjects (mean (SD) age 34 (9.9) years) were analysed retrospectively for a mean (SD) follow-up of 59.3 (45.5) months. Thirty patients (8.1%) developed a first thrombotic event during follow-up. Hypertension and medium/high levels of IgG aCL were identified by multivariate logistic regression analysis as independent risk factors for thrombosis. Thromboprophylaxis during high-risk and long-term periods was significantly protective.
  
  
  CONCLUSIONS
  Hypertension or medium/high titres of IgG aCL are risk factors for a first thrombotic event in asymptomatic aPL carriers and primary prophylaxis is protective.
authors.affiliation: Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy. amelia.ruffatti@unipd.it
authors.forename: A
authors.initials: A
authors.lastname: Ruffatti
authors.forename: T
authors.initials: T
authors.lastname: Del Ross
authors.forename: M
authors.initials: M
authors.lastname: Ciprian
authors.forename: M
authors.initials: M
authors.lastname: Nuzzo
authors.forename: M
authors.initials: M
authors.lastname: Rampudda
authors.forename: M T
authors.initials: MT
authors.lastname: Bertero
authors.forename: R
authors.initials: R
authors.lastname: Bergia
authors.forename: P
authors.initials: P
authors.lastname: Caramaschi
authors.forename: D
authors.initials: D
authors.lastname: Biasi
authors.forename: F
authors.initials: F
authors.lastname: Capsoni
authors.forename: L
authors.initials: L
authors.lastname: Montaguti
authors.forename: R
authors.initials: R
authors.lastname: Ruffini
authors.forename: A
authors.initials: A
authors.lastname: Brucato
authors.forename: U
authors.initials: U
authors.lastname: Picillo
authors.forename: V
authors.initials: V
authors.lastname: Fanelli
authors.forename: V
authors.initials: V
authors.lastname: Riccieri
authors.forename: A
authors.initials: A
authors.lastname: Piccoli
authors.forename: G
authors.initials: G
authors.lastname: Valesini
authors.forename: A
authors.initials: A
authors.lastname: Doria
authors.forename: P L
authors.initials: PL
authors.lastname: Meroni
authors.forename: A
authors.initials: A
authors.lastname: Tincani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000235:genetics / Q000276:immunology*; D004812:Epidemiologic Methods; D005260:Female; D006579:Heterozygote; D006801:Humans; D006973:Hypertension / Q000150:complications; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D013927:Thrombosis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D055815:Young Adult
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D007074:Immunoglobulin G